Delcath subgroup data links survival to tumor burden and LDH in uveal melanoma

New Phase 3 subgroup data suggest Delcath’s HEPZATO KIT improves survival in patients with lower tumor burden or LDH. Learn what this means for mUM treatment.

New Phase 3 subgroup data suggest Delcath’s HEPZATO KIT improves survival in patients with lower tumor burden or LDH. Learn what this means for mUM treatment.